Edelman - Clinical Trials

733 views

Published on

University of Maryland Baltimore
Experimental Therapeutics Symposium 2009

Published in: Education, Business
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
733
On SlideShare
0
From Embeds
0
Number of Embeds
135
Actions
Shares
0
Downloads
0
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

Edelman - Clinical Trials

  1. 1. Program Leader Douglas D. Ross, MD, PhD Clinical Program Leader Martin J. Edelman, MD Experimental Therapeutics Molecular & Structural Biology Hormone Responsive Cancers Viral Oncology (Developing) Tumor Immunology (Developing) X-Ray Crystallography Clinical Research Proteomics Flow Cytometry Experimental Therapeutics Biopolymer Tissue/ Biorepository Translational Biostatistics
  2. 2. Clinical Trials <ul><li>“ Ideal” studies are based upon laboratory work done at UMGCC and supported by peer reviewed funding. </li></ul><ul><li>Not always possible, practical or desirable </li></ul><ul><ul><li>Need to provide as full a menu as possible of trials for patients. </li></ul></ul><ul><ul><li>Need to support Cooperative Group efforts </li></ul></ul><ul><ul><li>Cooperation with NCI sponsored consortia </li></ul></ul><ul><ul><li>Collaboration with other investigators and industry necessary for advancement of our own projects </li></ul></ul>
  3. 3. All Therapeutic ET HRC TII 640 171 23 159 100 23 TII – All accruals to institutional/externally peer reviewed trials ET HRC Externally peer reviewed Institutional National group Industry All Therapeutic All Therapeutic 7 69 74 21 7 4 70 19 18 11 60 70 18 321 227 74
  4. 4. Trials Open to Accrual 7/08 – 6/09 Total Trials (240) Therapeutic (152) Non-Therapeutic (88) Accruals 7/1/08 – 6/30/09 Total: 834 Total Therapeutic: 282 (371 consented) Therapeutic Accruals: Institutional: 13%; Ext Peer Rev: 9% Natl Group: 46%; Industry: 32%
  5. 5. Experimental Therapeutics Pipeline Target Preclinical Phase I Phase II Phase III Nanoparticles S100 COX-2 Fulton, Rosenberg Horiba, Edelman UMGCC 0226 CALGB 30203 CALGB 30801 Weber, Sausville UCN-01 Fat nucleosides Hosmane, Edelman Swaan, Anjan, Sausville, Edelman Gojo, Sausville, Edelman UMGCC 0143 UMGCC 0507 UMGCC 0794
  6. 6. Experimental Therapeutics Pipeline Target Preclinical Phase I Phase II Phase III Suntharalingam, Edelman HPV Cullen, Suntha, Strome UMGCC 0782 HDAC Carrier, Ross, Badros, Gojo EGFR UMGCC 0443 Folate receptor PARP Gojo, Sausville Sausville, Edelman UMGCC 0643 UMGCC UMGCC 0733 RTOG 0839 RTOG 0436 UMGCC 0050 UMGCC 0710 UMGCC 0447 UMGCC 0743 UMGCC 0804 UMGCC 09xx

×